CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Cytek Biosciences Q3 revenue rises 2% on US growth

By Reuters News


Overview

  • Cell analysis solutions firm's Q3 revenue rose 2% yr/yr

  • Company's Q3 gross margin improved by nearly 600 basis points yr/yr

  • Company maintained midpoint of 2026 revenue guidance, narrowing the range


Outlook

  • Cytek Biosciences sees 2026 revenue between $208 mln and $211 mln

  • Company expects a strong finish to 2026 and continued market share gains


Result Drivers

  • US GROWTH AND HIGH-END INSTRUMENT DEMAND - Co said Q3 revenue growth was led by the U.S. market, with strong demand for high-end instruments and continued growth in service

  • RECURRING REVENUE - Co said recurring revenue from service and reagents increased, making up a larger share of total revenue

  • GROSS MARGIN EXPANSION - Co reported higher gross margin, citing improved product and service mix


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$53.23 mln

$52.80 mln (2 Analysts)

Q3 Net Loss

$6.10 mln

Q3 Adjusted EBITDA

$711,000

Q3 Pretax Loss

$6.91 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Reuters Recommended Reads

  • Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

  • Nov 3 - Revvity Q3 revenue beats estimates, raises FY guidance

  • Nov 3 - SOPHiA GENETICS Q3 revenue rises on US market strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.